Long-Term Androgen Deprivation Better Than Short-Term in Prostate Cancer

Share this content:

the Cancer Therapy Advisor take:

Two years of adjuvant androgen deprivation therapy (ADT) combined with high-dose radiotherapy improves control and overall survival in high-risk patients with prostate cancer compared to short-term ADT, according to a recent study published in The Lancet Oncology.

Spanish researchers led by Almudena Zapatero, PhD, of the Hospital Universitario de la Princesa conducted an open-label, multicenter, phase 3 randomized controlled trial from November 2005 to December 2010. They examined 178 patients with prostate cancer who received short-term ADT and 177 who received long-term ADT.

Median follow-up was 63 months, and the primary endpoint was biochemical disease-free survival.

The researchers found that 5-year biochemical disease-free survival, 5-year overall survival and 5-year metastasis-free survival were all significantly better in patients who received long-term ADT compared to short-term.

Additionally, they found that the effect of long-term ADT on survival was more evident in patients with high-risk disease compared to low-risk patients.

Long-Term Androgen Deprivation Better Than Short-Term in Prostate Cancer
Two years of adjuvant ADT combined with high-dose radiotherapy improves survival in prostate cancer.
The researchers aimed to determine whether long-term androgen deprivation was superior to short-term androgen deprivation when combined with high-dose radiotherapy. Longer follow–up is needed to determine whether men with intermediate–risk disease benefit from more than 4 months of androgen deprivation.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs